Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Payables (2017 - 2026)

Cogent Biosciences' Payables history spans 10 years, with the latest figure at $13.7 million for Q1 2026.

  • Quarterly Payables fell 2.9% to $13.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Mar 2026, down 2.9% year-over-year, with the annual reading at $9.5 million for FY2025, 20.89% down from the prior year.
  • Payables came in at $13.7 million for Q1 2026, up from $9.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $16.6 million in Q2 2025 to a low of $3.5 million in Q2 2022.
  • The 5-year median for Payables is $9.9 million (2023), against an average of $10.1 million.
  • Year-over-year, Payables surged 1174.6% in 2022 and then dropped 20.89% in 2025.
  • Cogent Biosciences' Payables stood at $5.8 million in 2022, then soared by 82.39% to $10.7 million in 2023, then grew by 12.75% to $12.0 million in 2024, then decreased by 20.89% to $9.5 million in 2025, then soared by 44.61% to $13.7 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Payables are $13.7 million (Q1 2026), $9.5 million (Q4 2025), and $16.0 million (Q3 2025).